[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 16, Issue 1 (6-2018) ::
3 2018, 16(1): 1-7 Back to browse issues page
Production, quality control, and biodistribution studies of 141Ce-EDTMP as a potential bone pain palliation agent
FATEMEH SOLTANI , SIMINDOKHT SHIRVANI ARANI , MAHDI SADEGHI * , SAMIRA HEIDARI , ALI BAHRAMI SAMANI , KAMAL YAVARI
Medical Physics Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Abstract:   (2441 Views)
The purpose of the present work was to introduce 141Ce-EDTMP as a novel potential future pain palliative agent to patients suffering from disseminated skeletal metastases and diagnostic imaging radioisotope as well. Cerium-141 [T1/2 = 32.501 days, Eβ (max) = 0.580 (29.8%) and 0.435(70.2%) MeV, Eγ = 145.44 (48.2%) keV] possesses radionuclidic properties suitable for use in palliative therapy of bone metastases. 141Ce also has gamma energy of 145.44 keV, which resembles that of 99mTc. Therefore, the energy window is adjustable on the Tc-99m energy because of imaging studies. 141Ce can be produced through a relatively easy route that involves thermal neutron bombardment on natural CeO2 in medium flux research reactors (4–5×1013 neutrons/cm2·s). The requirement for an enriched target does not arise. Ethylenediamine (tetramethylene phosphonic acid) (EDTMP) was synthesized and radiolabeled with 141Ce. The experimental parameters were optimized to achieve maximum yields (>99%). The radiochemical purity of 141Ce-EDTMP was evaluated by radio-thin layer chromatography. The stability of the prepared formulation was monitored for one week at room temperature, and results showed that the preparation was stable during this period (>99%). Biodistribution studies of the complexes carried out in wild-type rats exhibited significant bone uptake with rapid clearance from blood. The images showed high uptake of complex in bone after 72h and 2 weeks clearly. The percentage injected dose per gram of tissue (%ID/g) for each organ or tissue was calculated. The results show significant bone uptake with rapid clearance from blood. The properties of produced 141Ce-EDTMP suggest applying a new efficient bone pain palliative therapeutic agent to overcome metastatic bone pains.
 
 
Keywords: Cerium-141, Bone pain palliative, EDTMP, Radiopharmaceutical, Biodistribution
Full-Text [PDF 614 kb]   (1300 Downloads)    
Article Type: Research Article | Subject: Absorption, Distribution, Metabolism and Excretion
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

SOLTANI F, SHIRVANI ARANI S, SADEGHI M, HEIDARI S, BAHRAMI SAMANI A, YAVARI K. Production, quality control, and biodistribution studies of 141Ce-EDTMP as a potential bone pain palliation agent. 3 2018; 16 (1) :1-7
URL: http://ijpt.iums.ac.ir/article-1-286-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 16, Issue 1 (6-2018) Back to browse issues page
مجله داروشناسی و درمان شناسی ایران Iranian Journal of Pharmacology and Therapeutics
Persian site map - English site map - Created in 0.07 seconds with 39 queries by YEKTAWEB 4642